Celularity Inc (CELU) Stock Price, Quote & News

Company Profile

Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degene...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 768 2170

Website: www.celularity.com

Address:

170 Park Avenue, Florham Park, United States

silentmaxx Mar. 13 at 4:10 PM

$CELU

0 · Reply

luckydog2 Mar. 12 at 1:39 PM

$CELU Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities https://www.globenewswire.com/news-release/2026/03/12/3254647/0/en/Celularity-Reiterates-Strategic-Commercialization-Partnership-with-NEXGEL-Focused-on-Building-Biomaterials-Franchise-with-Established-Commercial-Products-and-New-510-k-Pathway-Prod.html

2 · Reply

silentsparrow Mar. 11 at 7:02 PM

$RNWF Tried to tell you. We still have 94 cents left to go. Dont miss out kids $BTCM $CELU $OPTT $JDZG

0 · Reply

luckydog2 Mar. 11 at 4:26 PM

$CELU

0 · Reply

GODofPoor Mar. 11 at 3:41 PM

$CELU just bought some 🤞

0 · Reply

ERQ Mar. 11 at 11:57 AM

$CELU Honestly I am more excited about this stock now than ever. They kept their manufacturing . They got cash and are now doing what they set out to do in the first place. The placental derived longevity therapy has always been Dr. Harri’s core focus. This is the future of medicine.

1 · Reply

Jeffartist Mar. 11 at 9:55 AM

$RNWF $BTCM $CELU $OPTT $JDZG

0 · Reply

silentsparrow Mar. 11 at 1:23 AM

$RNWF the 2 most bullish pictures i own! Worlds very 1st working fusion reactor! And the my main main Dr. B SAYING we have a live demo coming our way!!! Plenty of dd on our page! Not asking you to buy a milly shares. Just do some dd $BTCM $CELU $OPTT $JDZG

0 · Reply

luckydog2 Mar. 11 at 12:25 AM

$CELU

1 · Reply

Sacsofcash Mar. 11 at 12:22 AM

$CELU 1.3900 0.0000 (0.00%) Overnight: 8:00:25 PM EDT

0 · Reply

Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities

Mar 10, 2026, 8:30 AM EDT - 3 days ago

EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple Revenue

NXGL

Mar 10, 2026, 8:30 AM EDT - 3 days ago

Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy

Feb 10, 2026, 8:30 AM EST - 4 weeks ago

Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses

Dec 26, 2025, 8:30 AM EST - 2 months ago

Celularity CEO Comments on Centers for Medicare & Medicaid Services' Withdrawal of Skin Substitute Local Coverage Determinations

Dec 22, 2025, 4:01 PM EST - 2 months ago

Celularity Announces Closing of Financing Transactions

Dec 18, 2025, 2:10 PM EST - 3 months ago

Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision

Oct 30, 2025, 8:00 AM EDT - 4 months ago

Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care

Oct 14, 2025, 8:45 AM EDT - 5 months ago

Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease

Sep 3, 2025, 8:00 AM EDT - 6 months ago

Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance

Aug 22, 2025, 5:30 PM EDT - 7 months ago

Celularity Receives Nasdaq Notice Regarding Form 10-Q

Aug 18, 2025, 8:00 AM EDT - 7 months ago

Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt

Jul 9, 2025, 8:30 AM EDT - 8 months ago

Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law

Jul 1, 2025, 8:30 AM EDT - 9 months ago

Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies

Jun 10, 2025, 4:15 PM EDT - 9 months ago

Celularity Announces Chief Financial Officer Transition

Jun 2, 2025, 8:00 AM EDT - 10 months ago

Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology

May 9, 2025, 9:15 AM EDT - 11 months ago

Celularity Announces Full Year 2024 Operating and Financial Results

Apr 25, 2025, 5:30 PM EDT - 11 months ago

Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees

Apr 14, 2025, 8:00 AM EDT - 11 months ago

Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products

Feb 25, 2025, 8:00 AM EST - 1 year ago

Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products

Feb 24, 2025, 8:00 AM EST - 1 year ago

Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company

Dec 10, 2024, 8:00 AM EST - 1 year ago

Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter

Dec 6, 2024, 8:00 AM EST - 1 year ago

Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023

Nov 27, 2024, 5:00 PM EST - 1 year ago

Celularity Inc. Announces Receipt of Nasdaq Notification

Nov 20, 2024, 8:30 AM EST - 1 year ago

Celularity's Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific

Oct 23, 2024, 8:30 AM EDT - 1 year ago

Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel

Oct 18, 2024, 6:00 PM EDT - 1 year ago

Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal

Oct 16, 2024, 5:15 PM EDT - 1 year ago

Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.

Sep 5, 2024, 4:05 PM EDT - 1 year ago

Celularity to Present at H.C. Wainwright's 26th Annual Global Investment Conference

Aug 28, 2024, 4:45 PM EDT - 1 year ago

Celularity Appoints Richard J. Berman to its Board of Directors

Aug 23, 2024, 5:00 PM EDT - 1 year ago

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Jul 31, 2024, 8:30 AM EDT - 1 year ago

Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023

Jun 3, 2024, 8:38 AM EDT - 1 year ago

Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting

May 14, 2024, 9:15 AM EDT - 1 year ago

Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy

Apr 22, 2024, 8:00 AM EDT - 2 years ago

Celularity Inc. to Host Investor and Analyst Research & Development Day

Apr 19, 2024, 5:30 PM EDT - 2 years ago

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Apr 18, 2024, 4:30 PM EDT - 2 years ago

Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products

Apr 8, 2024, 9:00 AM EDT - 2 years ago

Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells

Mar 26, 2024, 9:00 AM EDT - 2 years ago

Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L

Mar 20, 2024, 9:15 AM EDT - 2 years ago

Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy

Mar 14, 2024, 9:15 AM EDT - 2 years ago

Celularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE Summit

Mar 12, 2024, 9:20 AM EDT - 2 years ago

Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress

Mar 7, 2024, 9:35 AM EST - 2 years ago

Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells

Feb 23, 2024, 4:10 PM EST - 2 years ago

Celularity Announces 1-for-10 Reverse Stock Split

Feb 14, 2024, 4:05 PM EST - 2 years ago

Celularity's Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease

Feb 1, 2024, 9:00 AM EST - 2 years ago

Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline

Jan 25, 2024, 9:00 AM EST - 2 years ago

Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions

Jan 18, 2024, 1:40 PM EST - 2 years ago

Celularity Releases CEO Letter to Shareholders

Jan 4, 2024, 1:00 PM EST - 2 years ago

Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare

silentmaxx Mar. 13 at 4:10 PM

$CELU

0 · Reply

luckydog2 Mar. 12 at 1:39 PM

2 · Reply

silentsparrow Mar. 11 at 7:02 PM

$RNWF Tried to tell you. We still have 94 cents left to go. Dont miss out kids $BTCM $CELU $OPTT $JDZG

0 · Reply

luckydog2 Mar. 11 at 4:26 PM

$CELU

0 · Reply

GODofPoor Mar. 11 at 3:41 PM

$CELU just bought some 🤞

0 · Reply

ERQ Mar. 11 at 11:57 AM

1 · Reply

Jeffartist Mar. 11 at 9:55 AM

$RNWF $BTCM $CELU $OPTT $JDZG

0 · Reply

silentsparrow Mar. 11 at 1:23 AM

0 · Reply

luckydog2 Mar. 11 at 12:25 AM

$CELU

1 · Reply

Sacsofcash Mar. 11 at 12:22 AM

$CELU 1.3900 0.0000 (0.00%) Overnight: 8:00:25 PM EDT

0 · Reply

focafoca99 Mar. 10 at 8:31 PM

$CELU is on the other side of that NexGel transaction, selling assets while entering an exclusive license setup

0 · Reply

ToxicAvenger Mar. 10 at 7:51 PM

$CELU shorts are just trying to get out.. look at the volume today...

0 · Reply

CantSeeStraight Mar. 10 at 7:37 PM

$CELU broke 1.37

0 · Reply

luckydog2 Mar. 10 at 6:37 PM

$CELU What does this mean? Celularity’s Approach to Senescence Targeting "Senoablation": CEO Dr. Robert Hariri uses the term "senoablation" to describe the targeted elimination of senescent cells that accumulate with age. Placental NK Cells: Celularity’s lead platform uses Natural Killer (NK) cells derived from the postpartum placenta. These cells are naturally programmed to identify and destroy senescent cells.

0 · Reply

luckydog2 Mar. 10 at 6:36 PM

$CELU The most interesting part of the news: <Following the transaction, Celularity will intensify its longevity focus on developing placental-derived cell therapies designed to address key biological drivers of aging, including cellular senescence, chronic inflammation, and tissue degeneration. The Company also intends to expand its commercial and clinical opportunities in jurisdictions that permit investigational use of cellular and biologic technologies under applicable state frameworks, including Florida, Texas, and Arizona, among others, in compliance with applicable law and regulatory requirements.>

0 · Reply

CharlieMungersghost Mar. 10 at 6:12 PM

$CELU I still think it could rocket. But I won't be risking another 5 years of bullshit. Good luck all.

0 · Reply

CharlieMungersghost Mar. 10 at 6:06 PM

$CELU hariri is the worst ceo I've come across. Nexgel will be immediately profitable after the acquisition of biomaterials. Hariri could've cut all the crap when lim khok was assisting him. He is a moonshot fool. Not a serious recurring cash flow guy.

0 · Reply

mf3rs Mar. 10 at 5:41 PM

$CELU hopefully they can file the 10k in time and don't miss out on the additional 20 mil.

0 · Reply

ERQ Mar. 10 at 5:16 PM

$CELU A major part of this deal is they massively reduce their overhead by getting rid of their sales force while keeping exclusive rights to manufacture the product. So we keep one of our growing revenue streams and go all in on a massive longevity opportunity, The longevity trend is catching interest in the market and I thing will really pick up second half the year.

0 · Reply

Nosay Mar. 10 at 4:46 PM

$CELU I expect an update from our CEO in the very near future on our direction. Makes sense now why he couldn’t have done it year to date while negotiating this deal.

2 · Reply

Chartwatcher1 Mar. 10 at 4:23 PM

$CELU long here, expect a contued run, GL

1 · Reply

SmartMoneyTradez Mar. 10 at 3:09 PM

$NIO $CELU on watch. Making moves

0 · Reply

Market Cap	36.91M
Revenue (ttm)	54.22M
Net Income (ttm)	-57.89M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-106.77%
Debt to Equity Ratio	-1.99

Volume	160,100
Avg Vol	185,138
Day's Range	N/A - N/A
Shares Out	28.84M
Stochastic %K	56%
Beta	0.79
Analysts	Sell
Price Target	$6.00